This inventor holds 6 USPTO granted patents and 1 published patent application. Top assignees: Omeros Corporation, Rigshospitalet, University of Copenhagen. Active years: 2017-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:




Years Active: 2017-2024
Title: Mikkel-Ole Skjodt: Innovator in Complement Activation Inhibition
Introduction
Mikkel-Ole Skjodt is a prominent inventor based in Frederiksberg C, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of chimeric inhibitor molecules. With a total of 6 patents, his work focuses on innovative solutions for medical conditions related to inflammation and autoimmunity.
Latest Patents
One of Mikkel-Ole Skjodt's latest patents involves chimeric inhibitor molecules of complement activation. This invention relates to novel chimeric molecules of ficolin-associated polypeptides, including fusion polypeptides designed for the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, and thrombotic or coagulopathic diseases. The patent also encompasses nucleic acid molecules encoding these fusion polypeptides, as well as the vectors and host cells used in their production.
Career Highlights
Throughout his career, Mikkel-Ole Skjodt has worked with notable organizations such as Omeros Corporation and Rigshospitalet. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative therapeutic solutions.
Collaborations
Mikkel-Ole Skjodt has collaborated with esteemed colleagues, including Peter Garred and Tina Hummelshoj Glue. These partnerships have further enriched his research endeavors and expanded the impact of his inventions.
Conclusion
Mikkel-Ole Skjodt stands out as a key figure in the field of biotechnology, with a focus on complement activation inhibition. His innovative patents and collaborations highlight his commitment to advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile